參考文獻(xiàn)/References:
[1] De Velasco G, Je Y, Bosse D, et al.Comprehensive meta analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients[J].Cancer Immunol Res,2017,5(4):312-318.[2] Suresh K, Psoter K J, Voong K R, et al.Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy[J].J Thorac Oncol,2019,14(3):494-502.[3] Cui P, Liu Z, Wang G,et al.Risk factors for pneumonitis in patients treated with anti-programmed death-1 therapy: A case-control study[J].Cancer Med,2018,7(8): 4115-4120.[4] Peng F, Hu D, Lin X, et al.The monocyte to red blood cell count ratio is a strong predictor of postoperative survival in colorectal cancer patients: the Fujian prospective investigation of cancer(FIESTA)study[J].J Cancer, 2017,8(6):967-975.[5] Putzu C, Cortinovis D L, Colonese F, et al.Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab[J].Cancer Immunol Immunother,2018,67(9):1349-1353.[6] Ho W J, Yarchoan M, Hopkins A, et al.Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas[J].J ImmunoTherapy Cancer,2018,6(1):84.[7] Guo W, Cai S, Zhang F, et al.Systemic immune-inflammation index(SII)is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer[J].Thoracic Cancer, 2019,10(4):761-768.[8] Fu H, Zheng J, Cai J, et al.Systemic immune-inflammation index(SII)is useful to predict survival outcomes in patients after liver trans-plantation for hepatocellular carcinoma within Hangzhou criteria[J].Cell Physiol Biochem, 2018,47(1):293-301.[9] Chen J H, Zhai E T, Yuan Y J, et al.Systemic immune-inflammation index for predicting prognosis of colorectal cancer[J].World J Gastroenterol,2017,23(34):6261-6272.[10] Fujisawa Y, Yoshino K, Otsuka A, et al.Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab[J].J Dermatol Sci,2017, 88(2): 225-231.[11] Liu H, Wu Y, Wang Z, et al.Pretreatment platelet-to-lymphocyte ratio(PLR)as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer[J].J Thorac Dis,2013,5(6): 783-789.[12] Martinov T, Fife B T.Fractionated radiotherapy combined with PD-1 pathway blockade promotes CD8 T cell-mediated tumor clearance for the treatment of advanced malignancies[J].Ann Transl Med,2016, 4(4):82.[13] Garon E B, Rizvi N A, Hui R, et al.Pembrolizumab for the treatment of non-small-cell lung cancer[J].N Engl J Med, 2015, 372(21): 2018-2028.